Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Beta Finch - Healthcare & Devices - EN cover art

Beta Finch - Healthcare & Devices - EN

Beta Finch - Healthcare & Devices - EN

Written by: Beta Finch
Listen for free

About this listen
Health insurers, medical device makers, and life sciences companies. AI-powered earnings call analysis for Healthcare & Devices (HEALTHCARE). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economics Personal Finance
Episodes
  • Cigna Q3 2026 Earnings Analysis
    Nov 6 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to listen to. I'm Alex...

    **JORDAN:** ...and I'm Jordan. Today we're digging into Cigna's third quarter 2026 results, and Alex, this is a company that's raising guidance while also telling investors "hey, 2027 is going to be a little weird."

    **ALEX:** Exactly, lots to unpack. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Good to have that out of the way. So let's get into the numbers.

    **ALEX:** Cigna posted adjusted revenue of $73.8 billion for the quarter, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. And here's the headline: they raised full-year 2026 EPS guidance to at least $30.60.

    **JORDAN:** That's a nice beat-and-raise story. And it's coming from two engines — Evernorth, their health services and pharmacy arm, and Cigna Healthcare, the traditional insurance side. Evernorth revenue grew 6% to $63.8 billion, with pretax earnings of $1.8 billion. Cigna Healthcare revenue was up 9% to $11.7 billion, pretax earnings of $1.2 billion.

    **ALEX:** And within Evernorth, the real star was Specialty and Care Services — that's Accredo, their specialty pharmacy, and CuraScript, their distribution business. Pretax earnings there grew 15% year-over-year to $1.1 billion.

    **JORDAN:** That's being driven by biosimilars and specialty generics hitting their stride. Generic Revlimid, a big oncology drug, is now at about 90% penetration. Biosimilar Humira and Stelara are seeing strong adoption too, especially with Cigna offering zero-dollar out-of-pocket options for patients.

    **ALEX:** It's a good reminder that the "boring" parts of healthcare — drug substitution, supply chain efficiency — can actually be huge profit drivers.

    **JORDAN:** Right, and on the Cigna Healthcare side, their medical care ratio — basically how much premium revenue goes out the door in claims — came in at 85%, right in line with expectations. Medical customers grew 2% year-to-date to 18.5 million, with particularly strong growth in their Select segment, which serves smaller employers.

    **ALEX:** Now let's talk strategy, because CEO Brian Evanko spent a lot of time on something called "Lead to 1." It's their big vision going forward.

    **JORDAN:** Lead to 1 is essentially about personalization at scale using data and AI. The stat that jumped out at me: 8% of patients account for 55% of total healthcare spending. So the whole strategy is built around identifying those complex, high-cost patients earlier and intervening before costs spiral.

    **ALEX:** They launched something called HealthSense in September — a tool that connects a patient's health needs, benefits, pharmacy coverage, and claims history so clinical teams get the full picture. It's starting with oncology.

    **JORDAN:** And they gave some compelling numbers around this — an integrated cancer patient journey can save $28,000 per person per year. That's not a typo, that's the scale of savings they're talking about for complex care coordination.

    **ALEX:** The other big strategic story is the "Signature" model — this is Cigna's attempt to reinvent pharmacy benefits. Instead of the traditional rebate-driven system, it's a fee-based, transparent model.

    **JORDAN:** Which matters because, let's be honest, PBMs have taken a lot of regulatory and public heat for opacity. Signature is designed to guarantee patients the lowest available out-of-pocket cost on prescriptions — they're calling it "Price Assure," and it's already saving about 30% on high-cost branded drugs for the rou

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Stryker Q3 2026 Earnings Analysis
    Oct 30 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Stryker's third quarter 2026 results. There's a lot to unpack here—an orthopaedics slowdown, a big robotics announcement, and a CEO transition all in one call.

    But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Right, and this one's actually a pretty meaty transcript, Alex. It's Kevin Lobo's last earnings call as CEO—57 quarters, which is a wild number—before he hands the reins to Spencer Stiles. So there's a bit of a "passing the torch" energy, but also some real business headwinds to address.

    **ALEX:** Let's start with the numbers. Stryker posted organic sales growth of 7.7% for the quarter. Adjusted EPS came in at $3.52, up about 10% year-over-year. On the surface, that sounds pretty solid.

    **JORDAN:** It does, but the devil's in the segment details. MedSurg and Neurotechnology grew 9.1%—that's the strong part of the story. Endoscopy was up double digits in the U.S., Medical grew 10%, Vascular grew 13%. But Orthopaedics—their bread-and-butter joint replacement business—only grew 5.9%, and within that, U.S. Knees were up just 1.3% and U.S. Hips actually declined slightly.

    **ALEX:** And that's really the headline story here, right? Management flagged a genuine market slowdown in U.S. hip and knee procedures.

    **JORDAN:** Exactly. Kevin Lobo was pretty candid about it. He pointed to patient affordability issues—higher deductibles, higher premiums—plus an uptick in insurance pre-authorization denials that's delaying patients from getting procedures done. He estimated the overall hip-and-knee market is now growing around 2.5%, which is a notable step down from the 5-6% range we've seen in recent years.

    **ALEX:** And it wasn't just market softness—Stryker also admitted they're not winning share at their historical pace.

    **JORDAN:** Right, and they were refreshingly honest about why. 2026 has been a messy year operationally. There was the cyber incident back in Q1, and then in July they completed their final SAP system implementation within Orthopaedics. Management said that actually delayed their visibility into real-time market conditions—they didn't fully grasp the slowdown until September, during an investor conference.

    **ALEX:** That's a pretty candid admission—basically saying "we were flying partially blind on our own numbers."

    **JORDAN:** It is. And it ties into why new products like Mako RPS and Triathlon Gold haven't scaled as fast as hoped—not a product problem, they said, but a commercial execution and distraction problem. The silver lining: they're bringing a power hip impaction tool to market next year, which fills a real gap in their hip portfolio and could help with competitive conversions.

    **ALEX:** Let's talk strategy, because there were two notable moves this quarter. First, they closed the acquisition of ZuriMED, which brings fiber-locker technology for rotator cuff repair—plugging nicely into their existing shoulder and sports medicine business.

    **JORDAN:** The bigger one, though, is the strategic investment in CMR Surgical. Stryker is becoming the exclusive U.S. sales agent for CMR's Versius soft-tissue robotic platform. This is interesting because Lobo was very clear this is intentionally structured to be low-risk—they're an investor and commercial partner for now, not an outright owner.

    **ALEX:** Why not just buy the whole thing?

    **JORDAN:** Lobo explained it well—he called it "derisking." Developing a soft-tissue robot from scratch is expensive and uncertain, and this lets Stryker test c

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Boston Scientific Q3 2026 Earnings Analysis
    Oct 28 2026
    More earnings analysis: https://betafinch.com
    Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Boston Scientific's third quarter 2026 results. And folks, there's a lot going on here — a cyber incident, competitive pressure, and some pretty candid talk about 2027 being a tough year. But before we get into it...

    This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Alright, let's set the scene. Boston Scientific, ticker BSX, has been a Wall Street darling for years — consistent growth, strong execution. But this quarter was rough.

    **ALEX:** Rough is right. Organic revenue grew just 1.5%, way below their guided range of 3% to 5%. Adjusted EPS came in at 73 cents, down 3% year-over-year, versus a guide of 80 to 82 cents.

    **JORDAN:** And the big culprit here is this cybersecurity incident that forced an operational outage. For about two weeks, they literally couldn't manufacture or ship product in some cases.

    **ALEX:** Right, management says that knocked off roughly 300 basis points of revenue growth and about 7 cents of EPS in the quarter. The good news — operations were fully back online by September 8th. But here's the kicker: the pain doesn't stop there. They're expecting another 200 to 300 basis points of headwind in Q4 because customers over-ordered at the end of Q3 to restock inventory, and now that has to normalize.

    **JORDAN:** It's like a hangover from the outage. You binge-order to protect your supply chain, and then the following quarter you're just burning through that excess inventory instead of placing new orders.

    **ALEX:** Exactly. And that's part of why Q4 guidance is actually a revenue *decline* — negative 1% to negative 3% organically, with EPS of 77 to 79 cents. For the full year 2026, they're now looking at about 4% organic growth and EPS of $3.16 to $3.18.

    **JORDAN:** Now, cyber incident aside, there's a bigger structural story here, and I think this is really the headline of the call. Two of their biggest growth engines over the last few years — Watchman, the left atrial appendage closure device, and their electrophysiology business built around FARAPULSE — are now dragging down total company growth.

    **ALEX:** Yeah, let's talk about EP first because that one's a bit alarming. Sales declined 5% year-over-year, down 8% in the U.S. Management openly admitted they're losing share as new pulsed-field ablation competitors enter the market with different catheter designs. And here's the thing — they don't expect real relief until they launch FARAWAVE Ultra, which got pushed to early 2028. Originally that was supposed to be sooner.

    **JORDAN:** And it's not just Ultra — their next-gen wide-area catheter, FARAFLEX, is now a 2029 launch. CEO Mike Mahoney and CFO John Monson were pretty transparent that pipeline timing has been a problem. Executive Joe Fitzgerald explained some of the delays — Ultra's held up by design verification and validation work, while FARAFLEX has had FDA negotiation delays and some operational hurdles in scaling up the clinical trial.

    **ALEX:** And then there's Watchman — down 7% in the U.S., though international grew 4%. Management's take is that physicians are reassessing referral patterns based on recent clinical evidence, and that's slowing the whole left atrial appendage closure market down, not just Boston Scientific specifically.

    **JORDAN:** They're throwing resources at it though — over 200 medical education events last quarter alone, more dedicated sales reps, and they've got a next-gen Watchman FLX Pro platform in a clinical trial now, aiming for a 2029 launch.

    **ALEX:** So here's where it gets really interest

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet